MK-1403 + FM2 + additive

MK-1403 + FM2 + additive is a specific oral tablet formulation of MK-1403, an investigational drug candidate developed by Merck Sharp & Dohme (MSD) for the treatment of atherosclerotic cardiovascular disease (ASCVD). MK-1403 is an oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that plays a critical role in cholesterol homeostasis by mediating the degradation of LDL receptors on the surface of hepatocytes. By inhibiting PCSK9, MK-1403 aims to increase the density of LDL receptors, thereby enhancing the clearance of circulating LDL cholesterol. The 'FM2 + additive' designation refers to a specific formulation (Formulation 2) that includes an additive, likely a permeation enhancer or stabilizer, intended to optimize the drug's oral bioavailability and pharmacokinetic profile. This formulation has been evaluated in Phase 1 clinical trials (e.g., NCT06143423) to assess its safety, tolerability, and relative bioavailability compared to other formulations in healthy adult participants.